0.65%
14.17%
4.39%
5.96%
23.07%
-34.64%
7.80%
AI Spotlight on REG1V
Company Description
Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally.The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities.
Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Market Data
| Last Price | 30.94 |
| Change Percentage | 0.65% |
| Open | 30.72 |
| Previous Close | 30.74 |
| Market Cap ( Millions) | 823 |
| Volume | 12723 |
| Year High | 35.84 |
| Year Low | 23.36 |
| M A 50 | 27.5 |
| M A 200 | 29.41 |
Financial Ratios
| FCF Yield | 1.93% |
| Dividend Yield | 1.23% |
| ROE | 19.00% |
| Debt / Equity | 2.96% |
| Net Debt / EBIDTA | -34.71% |
| Price To Book | 8.13 |
| Price Earnings Ratio | 43.06 |
| Price To FCF | 51.75 |
| Price To sales | 8.07 |
| EV / EBITDA | 26.85 |
News
- Jan -21 - 3 Promising Stocks Estimated To Be Up To 47.2% Below Intrinsic Value
- Dec -23 - 3 Stocks Estimated To Be Up To 49.2% Below Their Intrinsic Value
- Nov -13 - Revenio Group Oyj And 2 More Stocks Possibly Priced Below Their Estimated Value
- Oct -09 - Revenio Group Oyj (FRA:R0V) Q2 2024 Earnings Call Highlights: Strong Sales Growth and ...
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Ophthalmic Diagnostic Solutions
Expected Growth : 12 %
What the company do ?
Ophthalmic Diagnostic Solutions from Revenio Group Oyj provides innovative, high-quality diagnostic devices and software for eye care professionals to diagnose and manage eye diseases.
Why we expect these perspectives ?
Revenio Group Oyj's Ophthalmic Diagnostic Solutions segment growth is driven by increasing demand for early disease detection, advancements in optical coherence tomography (OCT) technology, and expanding presence in emerging markets. Additionally, growing prevalence of eye disorders, aging population, and rising healthcare expenditure contribute to the 12% growth.
Revenio Group Oyj Products
| Product Range | What is it ? |
|---|---|
| Revenio's Digital Health Solutions | Revenio's digital health solutions provide healthcare professionals with advanced tools to diagnose and monitor various eye conditions, including diabetic retinopathy and glaucoma. |
| Eye Clinic Management Software | Revenio's eye clinic management software streamlines clinical workflows, patient data management, and billing processes, improving efficiency and reducing costs. |
| Telemedicine Platforms | Revenio's telemedicine platforms enable remote consultations and monitoring, expanding access to eye care services, especially in underserved areas. |
| Artificial Intelligence (AI) and Machine Learning (ML) Solutions | Revenio's AI and ML solutions analyze medical images and data to aid in disease diagnosis, prediction, and prevention. |
| Medical Imaging and Diagnostics | Revenio's medical imaging and diagnostics solutions provide high-quality images and data analysis for accurate disease diagnosis and monitoring. |
Revenio Group Oyj's Porter Forces
Threat Of Substitutes
Revenio Group Oyj operates in a niche market with limited substitutes, but there are some alternatives available to customers.
Bargaining Power Of Customers
Revenio Group Oyj has a diverse customer base, and no single customer has significant bargaining power.
Bargaining Power Of Suppliers
Revenio Group Oyj relies on a few key suppliers, but there are alternative suppliers available in the market.
Threat Of New Entrants
Revenio Group Oyj operates in a niche market with high barriers to entry, making it difficult for new entrants to join the market.
Intensity Of Rivalry
Revenio Group Oyj operates in a competitive market with several established players, leading to intense rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 13.54% |
| Debt Cost | 5.43% |
| Equity Weight | 86.46% |
| Equity Cost | 10.42% |
| WACC | 9.74% |
| Leverage | 15.67% |
Revenio Group Oyj : Quality Control
Revenio Group Oyj passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CEVI.ST | CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the … |
| IBAB.BR | Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
| MEDI.OL | Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound … |
| LFWD | ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Revenio
A-Score
1-Year Total Return ->
🥈
Ion Beam Applications
A-Score
1-Year Total Return ->
🥉
CellaVision
A-Score
1-Year Total Return ->
4
Medistim
A-Score
1-Year Total Return ->
5
Xvivo Perfusion
A-Score
1-Year Total Return ->
6
